Edition:
United States

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

104.48USD
9 Dec 2016
Change (% chg)

$0.85 (+0.82%)
Prev Close
$103.63
Open
$104.47
Day's High
$107.56
Day's Low
$103.41
Volume
98,523
Avg. Vol
144,541
52-wk High
$139.79
52-wk Low
$82.06

LGND.OQ

Chart for LGND.OQ

About

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science,... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $2,183.65
Shares Outstanding(Mil.): 20.90
Dividend: --
Yield (%): --

Financials

  LGND.OQ Industry Sector
P/E (TTM): -- 40.79 30.36
EPS (TTM): -0.94 -- --
ROI: -4.15 -0.56 15.27
ROE: -5.80 -1.20 16.60

BRIEF-Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016

* Data shows statistically significant difference in modified partial remission; complete remission also observed

Nov 21 2016

BRIEF-Ligand Pharmaceuticals sees q4 2016 revenue $39 million to $43 million

* Q4 earnings per share view $1.37, revenue view $44.8 million -- Thomson Reuters I/B/E/S

Nov 03 2016

BRIEF-Ligand partner Melinta Therapeutics submits baxdela new drug application

* Ligand partner Melinta Therapeutics submits baxdela new drug application for hospital-treated skin infections

Oct 24 2016

BRIEF-Ligand Pharmaceuticals licenses four programs to Seelos Therapeutics

* Says under license agreement Ligand is entitled to receive an additional $3.5 million if Seelos becomes a public company

Sep 22 2016

BRIEF-Ligand enters OmniAb license agreement with TeneoBio inc

* Under license, TeneoBio will be able to use OmniFlic technology from OmniAb platform

Sep 16 2016

Retrophin kidney drug exceeds expectations in trial, shares jump

Retrophin Inc said its drug for a rare kidney disorder, which has no specific treatment, was found safe and effective in a mid-stage study, sending the company's shares soaring as much as 44 percent on Wednesday.

Sep 07 2016

UPDATE 3-Retrophin kidney drug exceeds expectations in trial, shares jump

* Retrophin shares rise as much as 44 pct (Adds details from conference call, analyst comment; updates shares)

Sep 07 2016

BRIEF-Ligand Pharmaceuticals gives LGD-6972 early trial results

* Single- and multiple-dose phase 1a, phase 1b studies demonstrated favorable safety, tolerability and pharmacokinetics

Aug 15 2016

BRIEF-Ligand Q2 adjusted earnings per share $0.50

* Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S

Aug 04 2016

BRIEF-Ligand announces licensing agreement with Nucorion Pharmaceuticals

* Ligand announces multi-program LTP technology licensing agreement with nucorion pharmaceuticals

Jul 29 2016

Earnings vs. Estimates